Home › Blog › Medical AI for doctors › OpenEvidence vs OneRx
OpenEvidence vs OneRx: Which Medical AI Is Better for Indian Doctors?
A doctor in India who types OpenEvidence vs OneRx into a search box is usually asking a simpler question underneath: is there a medical AI tool that will give a cited answer to a clinical question, quickly, and can it be used from here?
The short answer is that this kind of tool now exists, doctors in India are already using it between patients, and of the two names in the search, only one can be opened without a US credential. OpenEvidence is the larger product, built for verified US clinicians and not available to a doctor registered in India. OneRx is built in India and draws on Indian sources alongside international ones. The rest of this piece explains what a medical AI platform for doctors actually does, how it is being used, where OneRx fits, and why OpenEvidence stays out of reach.
By Sanjay Maurya, Business Head, OneRx
On this page: Medical AI · Clinical uses · OneRx · OpenEvidence · Comparison · Which one · FAQ · References
What a medical AI platform for doctors actually does
Strip away the marketing and the category is easy to describe. A doctor types a clinical question the way they would put it to a senior colleague, with the diagnosis, the comorbidities and the drugs already on board. The platform searches guidelines and published literature, writes a short structured summary, and attaches a reference to each point so the doctor can open the source. That is the whole product. It is a faster way to find and read the evidence, not a machine that makes the decision.
The better tools in this category share a few habits. They cite every claim rather than paraphrasing from memory, because an uncited answer cannot be checked. They stay current with guideline updates and regulatory approvals, because a summary built on a superseded guideline is worse than no summary. They say so when the evidence is thin or conflicting. And they stay in their lane: no diagnosis, no prescription, no patient-specific recommendation. OneRx puts it in one line on its doctor page : the platform summarises published evidence for the physician's interpretation, and the clinician always decides.
This is also what separates a medical AI platform from a general chatbot. A chatbot answers anything and can invent a reference that does not exist. A platform built for doctors restricts itself to medical sources and shows its working. The difference matters most at 6 pm in a crowded OPD, when nobody has time to verify a confident-sounding paragraph.
How doctors in India are using medical AI during the working day
The pattern that has emerged is less dramatic than the headlines suggest. Doctors are not asking an AI what to do. They are using it to close the gap between a question that comes up mid-consult and the evidence that answers it, which used to mean a search after clinic hours or a message to a colleague.
The use cases OneRx reports from its own users give a fair picture of the category:
- Between consults. A question arises during the OPD, the doctor puts it to the platform between patients, and has a referenced answer before the next decision point in the day.
- A guideline check mid-consult. Confirming the current first-line position for a presentation the doctor sees a few times a year, in the room, rather than from memory of the last edition read.
- An unfamiliar regimen. Confirming the schedule, the key contraindications and the monitoring points, with the citation attached for the notes.
- Preparing a case discussion. Pulling the pivotal trials and the current guideline position for each case before a departmental meeting, cited per question.
- Interpreting a specialist report. Mapping the findings in a genomic or other complex report to guideline-based options rather than working through the panel by hand.
- Finding a trial. Matching a patient's demographics, biomarkers and presentation to open studies, filtered by country.
- Patient materials. Generating a condition-specific document the patient can take home, built from the same query, which saves counselling time without cutting it short.
- Keeping current. A feed of new trial readouts and FDA and CDSCO approvals in one place, instead of chasing journals.
Two things are worth noticing in that list. Most of the uses are treatment and management questions rather than diagnosis, which matches what the largest study of clinician use of these tools found in the United States, where treatment questions outnumbered diagnosis by more than two to one. And none of the uses replaces the doctor. Each one gives back minutes that were being spent on searching, and hands the reading and the decision back to the clinician.
Where OneRx fits, and what it is built around
OneRx, a medical AI platform for doctors, was built in India for the way doctors here actually look things up. More than 3,000 doctors use it, it has answered more than 40,000 clinical questions, and it is in clinical use in eight countries: India, Nepal, Bahrain, Oman, Russia, Kazakhstan, Uzbekistan and Chad. It runs on the web, iOS and Android.
The design choice that matters most for an Indian reader is the source list. Alongside the major international guidelines (ESMO, ASCO, NICE, AHA, ACOG and IDSA among them), PubMed, ClinicalTrials.gov and journals such as The Lancet, JAMA, Nature and JCO, it draws on three Indian sources that a US-built tool has no reason to carry. ICMR, with the National Health Authority and WHO, has issued 157 Standard Treatment Workflows across 28 specialties that the National Medical Commission has asked every medical college to adopt. CDSCO is the central authority for the drugs marketed in India, and its SUGAM portal is where applications and approvals are now filed. CTRI, the Clinical Trials Registry of India run by ICMR, is the public record of trials registered in the country. A summary that knows what those three say is a summary that fits the ward the doctor is standing in.
The second design choice is local context. Each summary carries notes on availability, affordability and regulatory status for the doctor's own market, rather than US and European context alone, and the news feed carries CDSCO approvals next to FDA ones. A drug that is standard in an international guideline but has no Indian approval or no Indian distributor is flagged as such, instead of being presented as if the pharmacy downstairs stocks it.
On trust, three facts are enough. The platform has been evaluated in real practice, in a prospective multicentre study in India that is now peer reviewed and published in the International Journal of Medical Informatics ; oncology is where that published validation sits, and the platform itself serves doctors across specialties. It is CDSCO Registered and DPDP compliant, alongside HIPAA, SOC 2 Type 2, ISO 27001, ISO 13485 and IEC 62304. And it does not store or request identifiable patient information, cannot write orders into a hospital system, and for hospitals can be deployed on-premises with the institution choosing which guidelines and journals count as approved sources.
The honest limit is the one every doctor should apply anyway. Published validation outside oncology has not yet appeared, so in cardiology, obstetrics or infectious disease the sensible habit is to use the summary and the citations, open the citations, and judge the answer against the guideline the department follows.
OpenEvidence exists, and it is not available in India
OpenEvidence is the best-known product in this category and by some distance the largest. It is used by hundreds of thousands of US clinicians, has licensed content from major journals including NEJM and the JAMA Network, and is free for verified US clinicians. Nobody writing honestly about medical AI for doctors should pretend otherwise.
It is also, for a doctor in India, not an option. Its app listing describes it as free for verified US clinicians with an NPI required. An NPI is a 10-digit identifier that the US Centers for Medicare and Medicaid Services issues to health care providers; a doctor registered with the National Medical Commission does not have one. Its terms of use say the content is only applicable to use in the United States and to pharmaceuticals legally available there, and that the company may limit availability to any geographic area at its discretion. And in late April 2026 it withdrew from the European Union and the United Kingdom, citing regulatory uncertainty around AI systems including the EU AI Act. India has had no announcement either way, and no sign-up path.
Even for the doctor who holds a US NPI and practises in India, the fit is partial. The terms spell out that the content assumes US-available drugs, so the second check on CDSCO approval, Indian availability and price has to be done by hand.
Side by side, in one table
| Comparison | OneRx | OpenEvidence |
|---|---|---|
| Built for | Doctors in India and seven other countries | Verified US clinicians |
| Can a doctor in India sign up | Yes | No practical path; US NPI required |
| Indian sources | ICMR, CDSCO (SUGAM), CTRI | None listed |
| Local drug availability and price | Notes per market; CDSCO approvals in the news feed | Content stated as applicable to US-available pharmaceuticals |
| Regulatory and data | CDSCO Registered; DPDP compliant; no identifiable patient data stored; on-premises option for hospitals | HIPAA compliant; US terms; no India-specific statement |
| Published validation | Prospective multicentre study in India, peer reviewed | Large US usage study; independent audit of citations |
| EU and UK | Not among the eight countries listed | Withdrawn since April 2026 |
| Platforms | Web, iOS, Android | Web, iOS, Android |
Figures are as published by each company in November 2026; sources are linked in the sections above and listed at the end.
Which one to use
For a doctor registered in India, the choice makes itself. OpenEvidence cannot be opened, and OneRx can. The useful question is how to get value from it: ask in full clinical detail, read the summary, open the citations, and check local availability and price before a summary becomes a plan. That habit takes a minute and it is the whole difference between using a reference and trusting one.
For a doctor who holds a US NPI and practises in India, OpenEvidence works and its licensed full text is a real advantage on a pure literature question. The Indian layer still has to be done by hand, and OneRx is the simpler route when the question involves what is approved, available and affordable here.
For a hospital or medical director, the questions are about governance: where query data lives, which law covers it, whether the institution can restrict sources to its approved protocols, and whether the tool can write into the HIS. OneRx's hospital page answers all four, including on-premises deployment and a hard line that it cannot write orders; a pilot in one department with the medical director's team involved is how to find out whether the claims hold.
For a wider look at what general chatbots can and cannot safely do in clinical work, see the earlier pieces on safe use of ChatGPT for doctors and whether ChatGPT is reliable for medical advice .
Questions doctors ask
Is OpenEvidence available in India?
Not in any practical sense. The app listing says it is free for verified US clinicians and that an NPI is required, and the terms say the content applies to use in the United States. The company has not published an India policy, and it withdrew from the EU and UK in April 2026 over regulatory questions.
Is OneRx only for oncologists?
No. Oncology is where its published validation study was run and where its early users were concentrated. The platform is described by the company as a medical AI platform for doctors, and its sources span cardiology, obstetrics, infectious disease and general medicine through AHA, ACOG, IDSA and the ICMR workflows.
Does a medical AI platform give treatment advice?
No, and the good ones say so in writing. OneRx states that it summarises published evidence and guideline positions for the doctor's interpretation, and that final treatment choices and medico-legal responsibility stay with the treating clinician; OpenEvidence says its content is educational and not a substitute for clinical judgment. Both are evidence summaries. The decision stays with the doctor.
Is it safe to use during a busy OPD?
That is the use it is built for, with one condition: the citations get opened. A cited summary that nobody checks is only marginally better than a confident chatbot. A cited summary that takes a minute to verify is a faster route to the same evidence the doctor would have found by hand.
References
- OneRx homepage, accessed November 2026. https://www.onerx.ai/
- OneRx for doctors, accessed November 2026. https://www.onerx.ai/for-doctor
- OneRx for hospitals, accessed November 2026. https://www.onerx.ai/for-hospitals
- Prospective multicentre expert evaluation of an artificial intelligence-based oncology clinical decision support system across major cancer types in India. International Journal of Medical Informatics. 2026. https://www.sciencedirect.com/science/article/abs/pii/S138650562600479X
- National Medical Commission. Public notice on dissemination of ICMR Standard Treatment Workflows, 15 September 2025. https://medicaldialogues.in/pdf_upload/nmc-301276.pdf
- Directorate General of Health Services. Central Drugs Standard Control Organisation. https://dghs.mohfw.gov.in/cdsco.php
- CDSCO. Public notice on online services through the SUGAM portal. https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/fsugam.pdf
- Clinical Trials Registry - India (CTRI), ICMR. https://www.ctri.nic.in/Clinicaltrials/sect.php
- Patel VR, Finlayson SG, Liu-Hass M, et al. Clinician Use of an Artificial Intelligence-Enabled Clinical Information Platform. JAMA. 15 October 2026. https://jamanetwork.com/journals/jama/fullarticle/2855491
- OpenEvidence on Google Play, listing updated 28 September 2026. OpenEvidence on Google Play
- OpenEvidence Inc. Network Terms of Use, last updated 6 May 2025. https://openevidence.com/policies/terms
- Centers for Medicare and Medicaid Services. The National Provider Identifier fact sheet. https://cms.gov/files/document/npi-fact-sheet.pdf
- Cusano D. Breaking: OpenEvidence app access terminated in the UK and EU. Telehealth and Telecare Aware, 30 April 2026. https://telecareaware.com/breaking-openevidence-app-access-terminated-in-the-uk-and-eu/
